Updates

  • DPYD Screening
    The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering DPYD testing for the entire province effective March 1, 2023. DPYD screening is recommended for patients whose treatment plans include 5-fluorouracil (5FU) … Read more
  • Germline Confirmation of Pathogenic Variants Identified by Oncopanel
    This is an update to physicians who frequently order Oncopanel tumour testing through the Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer. As of July 1, 2022, germline confirmation can be ordered by any … Read more
  • Metastatic Prostate Cancer
    The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering tumour testing for patients with metastatic prostate cancer starting the week of May 24, 2022.  Key points regarding this new test offering … Read more
  • Acute Myeloid Leukemia MRD testing
    The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering minimal/measurable residual disease (MRD) testing for select patients with Acute Myeloid Leukemia (AML) starting the week of April 11, 2022. Key points … Read more
  • Launch of Focus Panel NGS testing
    The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will be commencing panel-based next generation sequencing (NGS) or “Focus Panel” testing starting May 2021. The AmpliSeq for Illumina Focus Panel enables rapid and accurate … Read more
  • MYD88 L265P testing
    The Cancer Genetics and Genomics Laboratory is offering a new test that interrogates the myeloid differentiation primary response 88 (MYD88) gene to detect the L265P mutation.  MYD88 L265P is identified in approximately 90% of confirmed … Read more
  • New FLT3 ITD and TKD test
    The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer has improved testing for clinically relevant variants in the Fms-related tyrosine kinase 3 gene (FLT3). Further details on the changes to testing can be found … Read more
  • KIT D816V/F – New test
    The Cancer Genetics and Genomics Laboratory’s (CGL) at BC Cancer has developed a new more sensitive test for detection of the KIT D816V and D816F mutations. Additional details on how the test has changed can … Read more